Clonidine and guanfacine in hypertension

Area of Science:

• Cardiology
• Pharmacology

Background:

• Essential hypertension is a common condition often requiring combination therapy.
• Alpha-adrenergic agonists like clonidine are used to manage hypertension.
• Guanfacine is another alpha-adrenergic agonist with a different pharmacokinetic profile.

Purpose of the Study:

• To compare the efficacy and safety of guanfacine versus clonidine in patients with inadequately treated hypertension.
• To assess the incidence and severity of rebound hypertension after abrupt withdrawal of guanfacine and clonidine.

Main Methods:

• A 24-week, double-blind, randomized, parallel study involving 42 patients with hypertension.
• Patients were treated with either guanfacine (1-3 mg/day) or clonidine (0.1-0.3 mg twice daily) in addition to chlorthalidone.
• Rebound hypertension was evaluated during a 7-day hospitalization after abrupt drug withdrawal.

Main Results:

• Both guanfacine and clonidine significantly reduced blood pressure, with mean reductions of 18/9 mm Hg and 14/8 mm Hg, respectively.
• Rebound hypertension was more pronounced and occurred earlier after clonidine withdrawal (Day 2) compared to guanfacine withdrawal (Day 4).
• Diastolic blood pressure elevations >= 10 mm Hg were observed in 40% of guanfacine patients and 64% of clonidine patients post-withdrawal.

Conclusions:

• Guanfacine is an effective and safe alternative to clonidine for managing essential hypertension.
• Once-daily dosing of guanfacine offers a favorable safety profile regarding rebound hypertension compared to twice-daily clonidine.